It develops neuroprotective and neuromodulatory agents to treat progressive neurological impairments characteristic of various nervous system disorders, including diabetic neuropathy and brain cancer.
The company’s product candidates include XERECEPT, a compound developed for the treatment of peritumoral brain edema, or swelling around brain tumors, which is Phase III Clinical Trials; and Viprinex, a compound developed for the treatment of acute ischemic stroke, which completed its Phase II clinical trials.
In addition, Neurobiological Technologies, through a research and marketing agreement with Merz Pharmaceuticals GmbH, offers Memantine, an orally dosed compound that restores the function of impaired neurons by modulation of the N-methyl-D-aspartate receptor.
The company was founded in 1987 and is headquartered in Richmond, California.
